diphenyleneiodonium has been researched along with rosiglitazone in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chan, JY; Chan, SH; Chang, AY; Ho, YH; Wu, CA; Wu, KL | 1 |
1 other study(ies) available for diphenyleneiodonium and rosiglitazone
Article | Year |
---|---|
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension.
Topics: Adenosine Triphosphate; Angiotensin II; Animals; Antioxidants; Blood Pressure; Blood Vessels; Catalase; Cell Respiration; Cyclic N-Oxides; Disease Models, Animal; Enzyme Inhibitors; Homeostasis; Humans; Hydrogen Peroxide; Hypertension; Imidazoles; Ion Channels; Male; Medulla Oblongata; Microinjections; Mitochondria; Mitochondrial Proteins; NADPH Oxidases; Onium Compounds; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphorylation; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Rosiglitazone; Spin Labels; Superoxide Dismutase; Superoxide Dismutase-1; Superoxides; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Transcription Factors; Transcriptional Activation; Transduction, Genetic; Uncoupling Protein 2; Up-Regulation | 2009 |